Tools and resources for ALUNBRIG(brigatinib)
ALUNBRIG Key Facts Booklet
A booklet for healthcare professionals containing a summary of the ALUNBRIG efficacy, tolerability and standard dosing information
Efficacy & Tolerability Overview
A booklet for healthcare professionals, containing an overview of ALUNBRIG key efficacy data, with general tolerability information
Information on ALUNBRIG standard dosing as a quick reference for healthcare professionals
Kim DW et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase positive non-small cell lung cancer: a randomized, multicenter phase II trial (ALTA). J Clin Oncol 2017;35:2490-8.
Watch Prof. Marianne Nicolson (Medical Oncologist from Aberdeen Royal Infirmary, Aberdeen, UK) discuss the unmet need in the treatment of advanced non-small cell lung cancer.
Patient Alert Card
A Patient Alert Card must be given to all patients prior to them beginning their treatment with ALUNBRIG. They should be monitored for adverse reactions, especially pulmonary adverse reactions, and the dose adjusted or discontinued if necessary, particularly in the first 7 days of treatment.
The Patient Alert Card describes the signs and symptoms of these serious pulmonary adverse reactions and what patients, and the healthcare professionals involved in their medical care, should do in the event that they experience any of these effects during or after treatment with ALUNBRIG.